2024
N-Methyl-d-Aspartate Receptor Antibody and Sensory Gating Deficits in Non-smoking, Minimal Antipsychotic Medication Exposure, and First-Episode Patients With Schizophrenia
Tong J, Yang K, Li W, Wang L, Yin Y, Zhou Y, Huang J, Zhang P, Zhao Y, Chen S, Fan H, Cui Y, Luo X, Tan S, Wang Z, Feng W, Tian B, Li C, Hong L, Tan Y. N-Methyl-d-Aspartate Receptor Antibody and Sensory Gating Deficits in Non-smoking, Minimal Antipsychotic Medication Exposure, and First-Episode Patients With Schizophrenia. Schizophrenia Bulletin 2024, sbae180. PMID: 39406395, DOI: 10.1093/schbul/sbae180.Peer-Reviewed Original ResearchFirst-episode schizophreniaSensory gating deficitsN-methyl-D-aspartate receptorsFirst-episode schizophrenia groupGating deficitsN-methyl-D-aspartateP50 ratioSensory gatingExposure to antipsychotic medicationAb levelsHealthy controlsAntipsychotic medication exposureFirst-episode patientsDiagnosis of schizophreniaImpaired sensory gatingP50 sensory gating deficitN-methyl-D-aspartate receptor antibodiesAntipsychotic medicationFirst-episodeNon-smoking healthy controlsP50 differenceSchizophreniaPartial correlation analysisEnzyme-linked immunosorbent assayDeficitsLigand‐gated ion channels as potential biomarkers for ADT‐mediated cognitive decline in prostate cancer patients
Verma S, Singh V, Nagampalli V, Ponsky L, Li C, Chao H, Gupta S. Ligand‐gated ion channels as potential biomarkers for ADT‐mediated cognitive decline in prostate cancer patients. Molecular Carcinogenesis 2024, 63: 1051-1063. PMID: 38482990, PMCID: PMC11096008, DOI: 10.1002/mc.23708.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyN-methyl-D-aspartate receptorsGamma-aminobutyric acidLigand-gated ion channelsType 1 angiotensin II receptorGlial cellsAndrogen signaling inhibitorsProstate cancer cell culture modelHigher risk of cognitive dysfunctionProstate cancer patientsPotential biomarkersBrain-derived neurotrophic factorCognitive dysfunctionIon channelsProtein-protein interaction network analysisAngiotensin II receptorsNuclear receptor subfamily 3 group C member 1Real-time polymerase chain reaction assayBrain glial cellsCytokine-cytokine receptor interactionCancer cell culture modelsAnalysis of genesGene-disease associationsInteraction network analysisPolymerase chain reaction assay
2021
N-methyl-D-aspartate receptor antibody and the choroid plexus in schizophrenia patients with tardive dyskinesia
Li N, Huang J, Zhang P, Tong J, Chen S, Cui Y, Tan S, Wang Z, Tian B, Li CR, Hong LE, Tian L, Tan Y. N-methyl-D-aspartate receptor antibody and the choroid plexus in schizophrenia patients with tardive dyskinesia. Journal Of Psychiatric Research 2021, 142: 290-298. PMID: 34411812, DOI: 10.1016/j.jpsychires.2021.08.010.Peer-Reviewed Original ResearchConceptsNMDAR antibody levelsNeuronal N-methyl-D-aspartate receptorAbnormal Involuntary Movement ScaleTardive dyskinesiaAntibody levelsCentral nervous systemChoroid plexusAIMS scoresN-methyl-D-aspartate receptor antibodiesSchizophrenia patientsN-methyl-D-aspartate receptorsOrofacial tardive dyskinesiaCP volumeNegative Syndrome ScaleEnzyme-linked immunosorbentNMDAR antibodiesAutoimmune abnormalitiesImmune disturbancesReceptor antibodiesHealthy controlsImmune barrierMovement ScaleNervous systemNTD groupSyndrome Scale